Edward Rebar
Chief Scientific Officer CPTx
Edward Rebar, Ph.D., is an R&D executive with over thirty years of experience building and translating cell engineering technologies. He most recently served as CTO of Sana Biotechnology, where he led the development of technologies and processes for scalable editing of T cells and stem cells for Sana’s oncology, autoimmunity and diabetes programs. Prior to Sana, Ed was with Sangamo Therapeutics, holding a number of roles including CTO. His work focused on improving the activity and precision of Sangamo’s zinc finger protein technologies. He earned his Ph.D. in biophysics and structural biology from MIT.
Seminars
Wednesday 10th February 2027
Panel Discussion: Intelligently Pairing Vectors, Payloads & Engineering Technologies for In Vivo Cell Therapy Success
12:15 pm
- Comparing viral and non-viral delivery approaches to understand how vector selection impacts safety, efficacy and cell-specific targeting
- Exploring advances in vector technology to successfully deliver DNA, mRNA and cRNA to unluck more durable expression with decreased therapeutic doses
- Developing scientifically guided frameworks to match delivery platforms, genetic cargo and tumour biology to accelerate translation to the clinic
Wednesday 10th February 2027
Utilising Non-Viral DNA Delivery to Define a Third Path for In Vivo CAR-T Therapies
1:45 pm
- Exploring how single-stranded DNA delivery combines the advantages of non-viral manufacturing with the durability required for lasting therapeutic responses
- Showcasing emerging preclinical evidence supporting durable, relapse-resistant CAR-T therapies generated entirely through non-viral approaches
